Envisia Therapeutics today announced that it will present data for its next generation product candidates, ENV515 for glaucoma and ENV705 for age-related macular degeneration (AMD), as well as new data for the company’s novel drug delivery systems designed for the posterior and anterior segments of the eye, at the Association for Research in Vision and Ophthalmology (ARVO) 2014 Annual Meeting.
Help employers find you! Check out all the jobs and post your resume.
